Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant mouse CST6
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intraperitoneal
01
Overview
RMCST6 is a recombinant form of cystatin M/E (CST6), which functions as a cysteine protease inhibitor. It is being investigated for its ability to ameliorate bone resorption, particularly in conditions like multiple myeloma (MM) and osteoporosis. The drug's mechanism involves increasing the expression of estrogen receptor alpha (ERα) and elevating intracellular estrogen concentrations within osteoclast precursor cells, thereby inhibiting their maturation and subsequent bone-resorbing activity.
02
Targets
CTSB (Cathepsin B)CTSK (Cathepsin K)CTSV (Cathepsin V)LGMN (Legumain)ESR1 (ERα)
Beyond the preview
Go deeper on recombinant mouse CST6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant mouse CST6.